Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Sibling Study Could Lead to Better Treatments

By Drug Discovery Trends Editor | November 4, 2008

Researchers at Huntsman Cancer Institute (HCI) believe they may be one step closer to understanding how certain forms of colon cancer develop.

In a study using siblings who have been diagnosed with colon cancer, scientists discovered similarities on a region of a particular chromosome, referred to as 7q31. Researchers believe that piece of genetic material may be causing a subset of colon cancers that run in families.

‘It’s those genetic similarities in colon cancer patients that would suggest that region holds a gene that’s causing colon cancer,’ says Deborah Neklason, PhD and lead investigator on the study.  Referred to as the Cancer Genetics Network ‘Sibling Pair Project,’ Neklason and other researchers analyzed the genetic material of 82 siblings. In addition to the discovery of a potential location of a cancer-causing gene, the research also shows siblings who share this genetic region tend to develop cancer 3.8 years earlier than siblings who do not. The study findings are published in the November 1, 2008 issue of Cancer Research.

Scientists already know roughly 30 percent of all colon cancers are a direct result of an inherited gene, but less than five percent of these genes have been identified.  ‘Those cases where the genes have been identified tend to be pretty dramatic,’ says Neklason. ‘Colon cancer develops at young ages and the cases are easier to figure out. It’s the other 25 percent that’s tough. These cases are more like sporadic colon cancer and are much more subtle,’ she says.

The findings could ultimately lead to a better understanding of the cellular process that results in cancer and its progression. It will likely pave the way for more targeted research that could someday result in a screening test to detect genetic forms of colon cancer.

Release Date: November 1, 2008
Source: University of Utah Health Services


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50